iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

NEW YORK, Jan.  06, 2020  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio”), a biologics innovator and contract manufacturer, announced today that it filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft (“Fraunhofer”) through an amended complaint. The new motion asserts that depositions conducted in late 2019 of personnel of Fraunhofer and its U.S. unit, Fraunhofer USA, Inc. (“FhUSA”), revealed that Fraunhofer exercised complete dominion and control over FhUSA to wrongfully access and direct use of iBio’s intellectual property on many occasions with new and different third parties. 

iBio Initiates New Litigation Against Fraunhofer.

NEW YORK, Dec.  23, 2019  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence (“AI”)/blockchain-driven vision system for pharmaceutical manufacturing, known as TrustPoint Fabric. Initial implementation will occur at iBio’s state-of-the-art production facility for the optimization of raw material documentation and verification activities.

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing

- Presentation Demonstrates Advantages of iBio’s Recently Launched FastGlycaneering Development Service™ -

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming

NEW YORK, Dec.  13, 2019  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE American: IBIO) (“iBio” or the “Company”), a leader in plant-based biologics manufacturing, announced today that on December 9, 2019, the Company received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) indicating the Company’s securities have been selling for a low price per share for a substantial period of time and pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the Company’s continued listing on the Exchange is predicated on the Company effecting a reverse stock split or otherwise demonstrating sustained improvement in its share price within a reasonable period of time, which the Exchange has determined to be no later than June 9, 2020.

iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan

NEW YORK, Dec.  10, 2019  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today unveiled the  FastGlycaneering  Development Service™, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators and biosimilar producers will now be able to take advantage of low-cost afucosylation controls, oligomannose modification capabilities, and more custom glycosylation techniques using iBio’s plant-based manufacturing platform in order to rapidly develop high-quality biobetters, novel antibody therapeutics, and biosimilars.

iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production

iBio to Support the 3D Bioprinting Industry with Enabling Biomaterials iBio to Support the 3D Bioprinting Industry with Enabling Biomaterials

iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative

NEW YORK, Oct.  25, 2019  (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $5,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

iBio, Inc. Prices $5,000,000 Public Offering

NEW YORK, Sept.  17, 2019  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”).

iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage

- Licenses to iBio’s Bio-Better Rituximab and FastPharming™ System Expand Commercial Partnership - - Licenses to iBio’s Bio-Better Rituximab and FastPharming™ System Expand Commercial Partnership -

iBio and CC-Pharming Expand Business Collaboration in China

NEW YORK, Aug.  19, 2019  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen (“rhCollagen”)-based bioink for 3D bioprinted organ transplants. iBio will collaborate with Lung Biotechnology PBC to scale-up production of rhCollagen in tobacco plants using iBio’s  FastPharming ™ System.

iBio Inks 3D Bioprinting Agreement

News for iBio Stock (IBIO)